Teva's CEO Present At Barclays Capital Global Healthcare Conference (Transcript)

Teva Pharmaceutical Industries Limited ( TEVA)

Barclays Capital Global Healthcare Conference Transcript

March 13, 2012 4:15 PM ET

Executives

Bill Marth – Chief Executive Officer

Analysts

Doug Tsao – Barclays Capital

Presentation

Doug Tsao Barclays Capital

So, good afternoon, everybody. My name is Doug Tsao. I cover U.S. Spec Pharma here at Barclays Capital. With us now is Bill Marth, CEO of Teva Americas. Obviously, I think almost everybody in the room is very familiar with Teva, which is the largest generics manufacturer in the world, as well as a leading brand player as well and certainly, increasingly so and certainly, part of the strategic direction for the company is to diversify the model. So, I think that will obviously be sort of a point of our conversation.

So to start off with, Bill, I think with a lot of the generics manufacturers who we’ve had present today, sort of started with this one question is, how you see your company, as well as the generics industry in the post-patent cliff world, which is certainly a concern that many people and investors sort of relate to me and ask me questions about, and I just wanted to get your perceptions on how Teva can successfully navigate that landscape?

Bill Marth

Well, thanks for the question, Doug. I think it’s really an interesting question and it’s a lot about your strategy as a company. Teva is really a company that is well-balanced between brand and generic. Our goal or our mission we feel is really to bring medications to patients around the world.

If you liked this article you might like

CEOs Are Dropping Like Flies

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed